Animal Health – Richard Markham, Cyvax Inc
Abstract for “Methods or compositions to prevent a condition”
“Provided are methods, compositions and kits for treating, preventing, or inhibiting a disease or condition. The pharmaceutical composition described herein may include a sequence of nucleic acids encoding an antigen fused with an immune cell product (e.g. MIP-3?) and an adjuvant. You can choose to get the antigen from bacteria, viruses, fungus or cancer. An antigen that is related to Alzheimer’s disease can be used.
Background for “Methods or compositions to prevent a condition”
“INCORPORATION BY RESEARCH”
“I. Overview”
“II. Nucleic Acid Sequence”
“III. Polypeptides”
“IV. “IV.
“V. Methods of Treatment or Prevention.”
“VI. Non-Human Animal Models”
“EXAMPLES”
“Example 1”
“Example 2”
“Example 3”
“Example 4”
“Example 5”
“Membrane Bound form of a P. falciparum Malaria vaccine”
“Example 6”
“Secreted Malaria Vaccine (GPI Deletion).”
“Example 7”
“Secreted Malaria Vaccine (Signal Sequence For Translocation and GPI Dual Deletion)”
“Example 8”
“Membrane Bound form of a Malaria Vaccine.”
“Example 9”
“Secreted form of a Malaria Vaccine.”
“Example 10”
“Immunization with Chemokine Fusion Vaccines Allows Cross Presentation Of Immunogens”
“Example 11”
“A MIP-3 Alpha Encoding DNA Fusion Vaccine Significantly Enhances Immune Responses To P. yoelii Antigens More Than the Enhanced Immunity Attained by In Vivo Electroporation.”
“Example 12”
“Comparative Analysis of Immune Responses to MIP-3?-CSP Fusion DNA Vaccine With Irradiated Sporozoites.”
“Example 13”
“Example 14”
“Vector VR1012 (4913 Bp; Map in FIG. 19)”
“Example 15”
“Partial Sequence hTPA and its Leader Seence (Underlined), Included in Construct – Restriction Sites PstI (Bold)
“Example 16”
“Human MIP-3alpha DNA”
“Example 17”
“Spacer between hMIP-3a & pfCSP (with BamHI Restriction site) (Underlined).”
“Example 18”
“Codon Optimized PfCSP (33 aa (22 NANP Repeats (SEQ ID NO: 47)))”
“Example 19”
“c-Myc tag with Spacer (in Single underline), Stop Codon(in Box) and Restriction Enzyme Websites XbaI BGlII (Double underline)”
“Example 20”
“Example 21”
“Example 22”
Summary for “Methods or compositions to prevent a condition”
“INCORPORATION BY RESEARCH”
“I. Overview”
“II. Nucleic Acid Sequence”
“III. Polypeptides”
“IV. “IV.
“V. Methods of Treatment or Prevention.”
“VI. Non-Human Animal Models”
“EXAMPLES”
“Example 1”
“Example 2”
“Example 3”
“Example 4”
“Example 5”
“Membrane Bound form of a P. falciparum Malaria vaccine”
“Example 6”
“Secreted Malaria Vaccine (GPI Deletion).”
“Example 7”
“Secreted Malaria Vaccine (Signal Sequence For Translocation and GPI Dual Deletion)”
“Example 8”
“Membrane Bound form of a Malaria Vaccine.”
“Example 9”
“Secreted form of a Malaria Vaccine.”
“Example 10”
“Immunization with Chemokine Fusion Vaccines Allows Cross Presentation Of Immunogens”
“Example 11”
“A MIP-3 Alpha Encoding DNA Fusion Vaccine Significantly Enhances Immune Responses To P. yoelii Antigens More Than the Enhanced Immunity Attained by In Vivo Electroporation.”
“Example 12”
“Comparative Analysis of Immune Responses to MIP-3?-CSP Fusion DNA Vaccine With Irradiated Sporozoites.”
“Example 13”
“Example 14”
“Vector VR1012 (4913 Bp; Map in FIG. 19)”
“Example 15”
“Partial Sequence hTPA and its Leader Seence (Underlined), Included in Construct – Restriction Sites PstI (Bold)
“Example 16”
“Human MIP-3alpha DNA”
“Example 17”
“Spacer between hMIP-3a & pfCSP (with BamHI Restriction site) (Underlined).”
“Example 18”
“Codon Optimized PfCSP (33 aa (22 NANP Repeats (SEQ ID NO: 47)))”
“Example 19”
“c-Myc tag with Spacer (in Single underline), Stop Codon(in Box) and Restriction Enzyme Websites XbaI BGlII (Double underline)”
“Example 20”
“Example 21”
“Example 22”
Click here to view the patent on Google Patents.